Skip to main content

This website is intended exclusively for healthcare professionals residing and/or working in Oman.

Home | go to homepage
SCIENCE
  • SCIENCE
  • Asthma
  • Atopic Dermatitis
  • Cardiovascular
    • Cardiovascular
    • Atherothrombosis
    • Dyslipidemia
    • Thrombosis
  • Diabetes
  • Eosinophilic Esophagitis
  • Multiple Sclerosis
  • Nasal Polyps
  • Prurigo Nodularis
  • Oncology and Rare Blood Disorder
    • Oncology and Rare Blood Disorder
    • Multiple Myeloma
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Meningitis
    • Pertussis & Polio
    • RSV
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Atopic Dermatitis
  • Cardiovascular
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
      • Clinical and economic value of SOLIQUA - Pharmacist perspective
  • Nasal Polyps
  • Rare Diseases
PRODUCTS
  • PRODUCTS
  • Amaryl®
  • Apidra®
  • Aprovel®
  • Aubagio®
  • Clexane®
  • Depakine®
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Nasal Polyps
  • Lantus®
  • Lemtrada®
  • Plavix®
  • Praluent®
  • Sarclisa
    • Sarclisa
    • Sarclisa®
    • Sarclisa Kd®
    • Sarclisa Pd®
  • Soliqua®
    • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
    • Soli-Simplify Study
  • Tavanic®
  • Toujeo®
    • Toujeo®
    • Toujeo®
    • For a Peaceful Ramadan
    • Time-in-Range
    • Real world Evidences
  • Zympass®
LOGIN
REGISTER
SEARCH
Home | go to homepage
LOGIN
REGISTER
SEARCH
Home | go to homepage
SCIENCE
  • SCIENCE
  • Asthma
  • Atopic Dermatitis
  • Cardiovascular
    • Cardiovascular
    • Atherothrombosis
    • Dyslipidemia
    • Thrombosis
  • Diabetes
  • Eosinophilic Esophagitis
  • Multiple Sclerosis
  • Nasal Polyps
  • Prurigo Nodularis
  • Oncology and Rare Blood Disorder
    • Oncology and Rare Blood Disorder
    • Multiple Myeloma
  • Rare Diseases
  • Vaccines
    • Vaccines
    • Influenza
    • Meningitis
    • Pertussis & Polio
    • RSV
PATIENT SUPPORT
  • PATIENT SUPPORT
  • Atopic Dermatitis
  • Cardiovascular
  • Diabetes
    • Diabetes
    • Tools And Resources
      • Tools And Resources
      • Toujeo Welcome Pack
      • Soliqua Welcome Pack
      • Pre-Ramadan assessment and Risk calculation for diabetic patients during Ramadan
      • Clinical and economic value of SOLIQUA - Pharmacist perspective
  • Nasal Polyps
  • Rare Diseases
PRODUCTS
  • PRODUCTS
  • Amaryl®
  • Apidra®
  • Aprovel®
  • Aubagio®
  • Clexane®
  • Depakine®
  • Dupixent®
    • Dupixent®
    • Atopic Dermatitis
    • Asthma
    • Nasal Polyps
  • Lantus®
  • Lemtrada®
  • Plavix®
  • Praluent®
  • Sarclisa
    • Sarclisa
    • Sarclisa®
    • Sarclisa Kd®
    • Sarclisa Pd®
  • Soliqua®
    • Soliqua®
    • Soliqua®
    • SoliMix Study
    • For a Peaceful Ramadan
    • Soli-Simplify Study
  • Tavanic®
  • Toujeo®
    • Toujeo®
    • Toujeo®
    • For a Peaceful Ramadan
    • Time-in-Range
    • Real world Evidences
  • Zympass®
  • LOGIN
  • REGISTER
  • SEARCH
    • Home
    • Sanofi in News

    Sanofi in News

    Discover headline news on how Sanofi is engaged with the medical community.

    Sanofi signs multi-pronged partnership with Dasman Diabetes Institute to intensify diabetes prevention in Kuwait

    Ministry of Health organizes "KiDS" program at Expo 2020 Dubai to promote diabetes awareness at schools

    Saudi Health Council, Sanofi partner to boost diabetes studies and research in the kingdom

    Home | go to homepage

    SANOFI, Level 3, One JLT, Jumeirah Lake Towers (JLT), DMCC, PO Box 53899, Dubai, UAE |

    Tel.: +971 4 550 3600 | Fax: +971 4 5521050

    For further Medical Information:

    please contact: +971 565776791 or Email: medical-information.gulf@sanofi.com

    To report an adverse event:

    please call: +971 561747001 or Email: Gulf.pharmacovigilance@sanofi.com

    To report any product technical complaints, kindly contact: Email: quality.greatergulf@sanofi.com

     

    MAT-OM-2100060/V4/Oct 2022

    • Legal notice
    • Cookie policy
    • Privacy policy
    • Sitemap
    • Change country

    YOU WILL NOW BE LEAVING THE SITE

    By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
    Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.

    Continue
    This website is intended exclusively for healthcare professionals residing and/or working in Oman.
     
    Please choose if you are a healthcare professional and wish to continue on this site or if you are a member of the public to be redirected to the Sanofi website.